BCG039 / Biocytogen - LARVOL DELTA

Preclinical study of BCG039, a Nectin-4×TROP2 bispecific ADC, in urothelial carcinoma and other solid tumor models (AACR 2026) - "It is a clinically validated target for mUC with enfortumab vendotin (EV) and pembrolizumab combination as the newly established SOC for first-line metastatic and locally advanced UC. BCG039, a bsADC targeting Nectin-4 and TROP2, showed superior anti-tumor efficacy in mice compared to single-targeting parental ADCs and relevant benchmark ADCs. The cooperative interaction of the two arms may also help reduce the toxicity observed with single-targeting ADCs against these targets in mUC."

ADC • Bispecific • Preclinical • Oncology • Solid Tumor • Urothelial Cancer • NECTIN4 • TACSTD2 • TOP1